Cassava Sciences Inc
Research Cassava Sciences Inc (SAVA) on Bullrun: market cap USD 87.92M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerSAVA
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 87.92M
- Financial periodFY2025
- RevenueUSD 0
- Net income-USD 90.97M
- Free cash flow-USD 32.83M
Valuation Snapshot
latest market cap is USD 87.92M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 90.97M | -USD 32.83M | n/a | -1.88 | USD 95.50M | n/a | USD 74.40M |
| FY2024 | USD 0 | -USD 24.34M | -USD 117.03M | n/a | -1.46 | USD 128.57M | n/a | USD 145.70M |
| FY2023 | USD 0 | -USD 97.22M | -USD 82.44M | n/a | -2.32 | USD 121.14M | USD 0 | USD 137.47M |
| FY2022 | USD 0 | -USD 76.25M | -USD 80.23M | n/a | -1.9 | USD 201.02M | USD 139.00K | USD 227.54M |
| FY2021 | USD 0 | -USD 32.39M | -USD 52.41M | n/a | -0.82 | USD 233.44M | USD 236.00K | USD 253.92M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-03-20 | USD 87.92M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 95.65M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 113.76M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 950.75M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 1.23B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 1.75B | n/a | n/a | n/a |
About Cassava Sciences Inc
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. Cassava Sciences, Inc. was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Cassava Sciences Inc's market cap?
Cassava Sciences Inc's market capitalization is USD 87.92M.
What does Cassava Sciences Inc do?
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. Cassava Sciences, Inc. was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company was incorporated in 1998 and is based in Austin, Texas.